

August 12, 2025

SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director,
President and Chief Executive Officer
Noritaka Narimiya
Executive Corporate Officer and Chief Financial Officer
TEL: +81-3-5472-1125

Notice Regarding Adjustment of Conversion Price

SymBio Pharmaceuticals Limited (the “Company”) hereby announces that, in conjunction with the issuance of the 65th to 67th Stock Acquisition Rights through a third-party allotment to EVO FUND, as resolved at the Board of Directors meeting held on Tuesday, July 22, 2025, the conversion prices of the convertible bonds with stock acquisition rights will be adjusted as follows.

1. Adjustment of Conversion Price

Name of convertible bonds	Conversion price after adjustment	Conversion price before adjustment
SymBio Pharmaceuticals Limited's 4th Unsecured Convertible Bonds with Stock Acquisition Rights	¥179.9	¥182.7
SymBio Pharmaceuticals Limited's 5th Unsecured Convertible Bonds with Stock Acquisition Rights	¥168.3	¥171.0
SymBio Pharmaceuticals Limited's 7th Unsecured Convertible Bonds with Stock Acquisition Rights	¥155.0	¥157.5

2. Applicable Date

From Tuesday, August 12, 2025

3. Reason for Adjustment

The conversion prices will be adjusted because the initial exercise prices of the 65th to 67th Stock Acquisition Rights, issued through a third-party allotment to EVO FUND as resolved at the Board of Directors meeting held on Tuesday, July 22, 2025, are lower than the market value stipulated in Item 14, Clause (4)-4)(iii)(b) of the Terms and Conditions of the 4th, 5th, and 7th Unsecured Convertible Bonds with Stock Acquisition Rights issued to Cantor Fitzgerald Europe.